Manish A. Shah, MD, discusses the results from the randomized phase III GAMMA-1 trial looking at andecaliximab in patients with untreated HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Manish A. Shah, MD, director of Gastrointestinal Oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the results from the randomized phase III GAMMA-1 trial looking at andecaliximab in patients with untreated HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Overall, the results were disappointing, Shah says. While andecaliximab demonstrated an improved overall response rate, there was no improvement in progression-free survival or overall survival in the unselected patient population. However, patients over the age of 65 seemed to have benefit.
Investigators conducted a sensitivity analysis and split the groups according to age to see if there was a step-wise increased benefit with the youngest group to the oldest. Shah says there was, suggesting there may be a signal here. More work must be done in order to find factors that may lead to this specific sensitivity in the older patient population, Shah concludes.
See more from the 2019 Gastrointestinal Cancers Symposium.